Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

Background Subjective cognitive decline (SCD) represents the first early symptomatic stage of Alzheimer's disease (AD). Objective We aimed to investigate the relationships between features in SCD and to assess the importance of these features in the future development of dementia to inform a targeted management protocol. Methods 440 SCD patients underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Relationships among features were first assessed univariately, focusing on differences across stratified subgroups. To capture multivariate associations, we applied network analysis using a Markov Random Field. Finally, baseline features were related to dementia progression using an XGboost machine learning model. Results Women comprising 68.9% of the cohort, were generally younger at onset, had lower APOE ε4 prevalence, and differed in neuropsychological performance compared to men. Older patients (age >60) exhibited a higher prevalence of APOE ε4 and cerebral small vessel disease. Patients with depressive symptoms demonstrated lower cognitive performance across multiple domains. Network analysis indicated complex interconnections among gender, cognitive reserve, SCD severity, and depressive symptoms. The XGboost model achieved 74% accuracy in predicting progression to dementia, identifying age at onset, mini-mental state examination scores, and APOE genotype as the most predictive factors. Conclusions This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. By identifying key predictive features, we propose a personalized management protocol aimed at optimizing care for individuals with SCD. Trial registration number: NCT05569083, registration date: 2019-05-30

Key findings

Why it matters

In 440 people with subjective cognitive decline followed for a median of 10 years, a machine learning model predicted progression to dementia with 74% accuracy, and features such as gender, cognitive reserve, subjective cognitive decline severity, and depressive symptoms were interconnected. This is a prediction and management-protocol study, not a treatment or cure.

Study details

How this study scored 44/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 44 of 100.44 of 100 points earned56 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 9.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Valentina Bessi: h-index 35 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Pavia: institution h-index 809 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41603334)
Free to read 2 / 2 Free to read
Total 44 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Mazzeo, S., Lassi, M., Padiglioni, S., Vergani, A. A., Moschini, V., Scarpino, M., et al. (2026). Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877261416117

Vancouver

Mazzeo S, Lassi M, Padiglioni S, Vergani AA, Moschini V, Scarpino M, et al. Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic. Journal of Alzheimer s Disease. 2026. doi:10.1177/13872877261416117. PMID: 41603334.

BibTeX

@article{mazzeo2026-41603334,
  author  = {Mazzeo, Salvatore and Lassi, Michael and Padiglioni, Sonia and Vergani, Alberto Arturo and Moschini, Valentina and Scarpino, Maenia and Giacomucci, Giulia and Burali, Rachele and others},
  title   = {{Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic}},
  journal = {Journal of Alzheimer s Disease},
  year    = {2026},
  doi     = {10.1177/13872877261416117},
  pmid    = {41603334},
  url     = {https://doi.org/10.1177/13872877261416117}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Mild cognitive impairment

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →